A5071076758- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
- Advanced Graph Theory Research
- Esophageal Cancer Research and Treatment
- Data Management and Algorithms
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Gastrointestinal Tumor Research and Treatment
- Complexity and Algorithms in Graphs
- Cancer Treatment and Pharmacology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Metastasis and carcinoma case studies
- Colorectal and Anal Carcinomas
- Economic and Financial Impacts of Cancer
- Computational Geometry and Mesh Generation
- Cancer Immunotherapy and Biomarkers
- semigroups and automata theory
- Sex and Gender in Healthcare
- Optimization and Search Problems
- Cancer Genomics and Diagnostics
- Colorectal Cancer Surgical Treatments
- Transportation Planning and Optimization
- Multiple and Secondary Primary Cancers
- Medication Adherence and Compliance
University of Lausanne
2016-2025
European Organisation for Research and Treatment of Cancer
2021-2025
University Hospital of Lausanne
2015-2024
Ludwig-Maximilians-Universität München
2024
LMU Klinikum
2024
Technische Universität Dresden
2023
Karlsruhe Institute of Technology
2012-2022
University of Tübingen
2020-2022
Breast Center
2022
Ludwig Cancer Research
2022
The OligoMetastatic Esophagogastric Cancer (OMEC) project aims to provide clinical practice guidelines for the definition, diagnosis, and treatment of esophagogastric oligometastatic disease (OMD).
LBA331 Background: 10-20% of GC are HER-2 positive. The role perioperative anti-HER2-directed treatment is yet undefined. Methods: This randomized, open-label phase II-trial investigates the benefit chemotherapy (CT) alone or in combination with either T and P for HER-2+ gastric (GC) esophagogastric junction cancer (EGJC). 172 patients (pts) centrally confirmed, positive status resectable EGJC (UICC TNM stages Ib-III) were included. Pts randomized a 1:2:2 ratio to: Arm A (CT alone) (35 pts);...
We consider two approaches that model timetable information in public transportation systems as shortest-path problems weighted graphs. In the time-expanded approach, every event at a station, e.g., departure of train, is modeled node graph, while time-dependent approach graph contains only one per station. Both have been recently considered for (a simplified version of) earliest arrival problem, but little known about their relative performance. Thus far, there are theoretical arguments...
10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, GC. When pertuzumab (P) was added neoadjuvant T and CT, a significant increase histopathological complete response rate observed breast cancer. This study aims investigate the benefit using both HER2 targeting drugs (T alone or combination + P), perioperative CT for localized is prospective, randomized, open-label,...
Perioperative chemotherapy plus surgery is one recommended standard treatment for patients with resectable gastric and esophageal cancer. Even a multimodality more than half of will relapse following surgical resection. Patients who have poor response to neoadjuvant an incomplete (R1) resection or metastatic lymph nodes in the specimen (N+) are especially at risk recurrence. Current clinical practice continue same adjuvant setting as before surgery. In phase II randomised EORTC VESTIGE trial...
An overlay graph of a given G = ( V , E ) on subset S ⊆ is with vertex set and edges corresponding to shortest paths in . In particular, we consider variations the multilevel used Schulz et al. [2002] speed up shortest-path computation. this work, follow present several selection criteria, along two general strategies applying these determine graph's vertices. The main contribution systematic experimental study where investigate impact criteria graphs resulting speed-up achieved for...
Abstract Background Adjuvant chemotherapy is a standard treatment option for patients with stage III and high-risk II colon cancer. Sex one of several factors responsible the wide inter-patient variability in drug responses. Amalgamated data on effect sex toxicity current adjuvant colorectal cancer are missing. Methods The objective our study was to compare incidence severity major toxicities fluoropyrimidine- (5FU or capecitabine) based chemotherapy, without oxaliplatin, between male female...
Despite the promising therapeutic effects of immune checkpoint blockade (ICB), most patients with solid tumors treated anti-PD-1/PD-L1 monotherapy do not achieve objective responses, tumor regressions being partial rather than complete. It is hypothesized that absence pre-existing antitumor immunity and/or presence additional suppressive factors at microenvironment are responsible for such failures. therefore clear in order to fully exploit potential PD-1 therapy, response should be...